Close Menu

NEW YORK (GenomeWeb) — Regulus Therapeutics announced this week that it has closed its previously announced public stock offering, raising $103.5 million through the transaction.

The company sold 6.1 million shares at $17 apiece. Roughly 4.8 million shares were sold by Regulus, with the remainder being sold by former parent firm Isis Pharmaceuticals.

Regulus expects its net proceeds from the offering to be about $76.1 million after expenses. The company will not receive any money from the sale of Isis' shares.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.

He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.

Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.

In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.